Association of serum glypican-4 levels with cardiovascular risk predictors in women with polycystic ovary syndrome - a pilot study.
OBJECTIVE
Glypican-4 (Gpc4) is an adipokine which interacts with the insulin receptor and affects insulin sensitivity in proteoglycans. Insulin resistance plays a crucial role in the etiology of polycystic ovary syndrome (PCOS). PCOS is associated with metabolic disturbances such as abdominal obesity, dyslipidemia and type 2 diabetes. Thus, higher levels of Gpc4 released from visceral adipose tissue in women with PCOS may suggest an increased risk of cardiovascular disease (CVD).


METHODS
The aim of this pilot study was to determine whether the serum Gpc4 level is associated with cardiovascular risk predictors in women with PCOS.


METHODS
Sixty-two women with PCOS according to the Rotterdam criteria (20-35 years old) and 43 healthy controls were studied. Cardiovascular risk predictors such as obesity indices, fat deposits according to dual-energy X-ray absorptiometry, biochemical lipid profile parameters and Homeostasis Model Assessment were estimated.


RESULTS
The serum Gpc4 level in PCOS women was significantly higher (2.61 ± 1.17 ng/ml) than in the control group (1.55 ± 0.47 ng/ml) and correlated with waist circumference, waist-to-hip ratio, total fat and android fat deposit to gynoid fat deposit ratio only in the PCOS group.


CONCLUSIONS
The Gpc4 level was higher in the PCOS group and correlated with CVD risk predictors, especially fat distribution.
a Department of Endocrinology , Diabetology and Isotope Therapy, Wroclaw Medical University , Wroclaw , Poland .
Diana
D
Jędrzejuk
b Department of Health Promotion , Faculty of Physiotherapy, University School of Physical Education , Wroclaw , Poland , and.
Felicja
F
Lwow
a Department of Endocrinology , Diabetology and Isotope Therapy, Wroclaw Medical University , Wroclaw , Poland .
Justyna
J
Kuliczkowska-Płaksej
c First Department of Gynecology and Obstetrics, Wroclaw Medical University , Wroclaw , Poland.
Lidia
L
Hirnle
a Department of Endocrinology , Diabetology and Isotope Therapy, Wroclaw Medical University , Wroclaw , Poland .
Anna
A
Trzmiel-Bira
a Department of Endocrinology , Diabetology and Isotope Therapy, Wroclaw Medical University , Wroclaw , Poland .
Agnieszka
A
Lenarcik-Kabza
a Department of Endocrinology , Diabetology and Isotope Therapy, Wroclaw Medical University , Wroclaw , Poland .
Katarzyna
K
Kolackov
a Department of Endocrinology , Diabetology and Isotope Therapy, Wroclaw Medical University , Wroclaw , Poland .
Łukasz
Ł
Łaczmański
b Department of Health Promotion , Faculty of Physiotherapy, University School of Physical Education , Wroclaw , Poland , and.
Andrzej
A
Milewicz
D000328:Adult; D002318:Cardiovascular Diseases / Q000097:blood* / Q000150:complications; D016022:Case-Control Studies; D005260:Female; D053673:Glypicans / Q000097:blood*; D006801:Humans; D050152:Intra-Abdominal Fat / Q000378:metabolism; D010865:Pilot Projects; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications; D018570:Risk Assessment; D055815:Young Adult
C492044:GPC4 protein, human; D053673:Glypicans
Cardiovascular risk predictors; glypican-4; polycystic ovary syndrome